La terapia dell'ipertensione arteriosa: benefici, costi, sfide.

Translated title of the contribution: Therapy of arterial hypertension: benefits, costs, challenges

A. Zanchetti

Research output: Contribution to journalArticle

Abstract

For more than 30 years the benefits of antihypertensive therapy have been assessed by randomized trials measuring cardiovascular events. Even greater benefits are found if prevention of congestive heart failure, left ventricular hypertrophy, and progression to more severe hypertension are considered. Quantifying the benefits in order to calculate cost-effectiveness of treatment is not easy, however. Taking absolute risk and absolute benefit as a guide to treatment decision, though an important approach, may result in limiting therapy to elderly and complicated hypertensives only. Furthermore randomized trials, whose duration is necessarily short, are likely to underestimate treatment benefits. An alternative is the actuarial approach, by which treatment benefits are calculated from the actuarial data showing the reduction in life expectancy associated with any given blood pressure increase. The cost of antihypertensive therapy per year of life gained, as calculated by the actuarial approach, is much lower than the cost calculated on the basis of the outcomes of randomized trials. In an uncertain area such as that of cost-effectiveness evaluation, it is important that both approaches be brought to the consideration of physicians, patients, politicians, and officers of national health systems.

Original languageItalian
JournalAnnali Italiani di Medicina Interna
Volume11 Suppl 2
Publication statusPublished - Oct 1996

Fingerprint

Cost-Benefit Analysis
Hypertension
Antihypertensive Agents
Therapeutics
Costs and Cost Analysis
Left Ventricular Hypertrophy
Life Expectancy
Heart Failure
Blood Pressure
Physicians
Health

ASJC Scopus subject areas

  • Internal Medicine

Cite this

La terapia dell'ipertensione arteriosa : benefici, costi, sfide. / Zanchetti, A.

In: Annali Italiani di Medicina Interna, Vol. 11 Suppl 2, 10.1996.

Research output: Contribution to journalArticle

@article{678b9f7a809e41c09a5bed988659cf99,
title = "La terapia dell'ipertensione arteriosa: benefici, costi, sfide.",
abstract = "For more than 30 years the benefits of antihypertensive therapy have been assessed by randomized trials measuring cardiovascular events. Even greater benefits are found if prevention of congestive heart failure, left ventricular hypertrophy, and progression to more severe hypertension are considered. Quantifying the benefits in order to calculate cost-effectiveness of treatment is not easy, however. Taking absolute risk and absolute benefit as a guide to treatment decision, though an important approach, may result in limiting therapy to elderly and complicated hypertensives only. Furthermore randomized trials, whose duration is necessarily short, are likely to underestimate treatment benefits. An alternative is the actuarial approach, by which treatment benefits are calculated from the actuarial data showing the reduction in life expectancy associated with any given blood pressure increase. The cost of antihypertensive therapy per year of life gained, as calculated by the actuarial approach, is much lower than the cost calculated on the basis of the outcomes of randomized trials. In an uncertain area such as that of cost-effectiveness evaluation, it is important that both approaches be brought to the consideration of physicians, patients, politicians, and officers of national health systems.",
author = "A. Zanchetti",
year = "1996",
month = "10",
language = "Italian",
volume = "11 Suppl 2",
journal = "Annali Italiani di Medicina Interna",
issn = "0393-9340",
publisher = "CEPI s.r.l.",

}

TY - JOUR

T1 - La terapia dell'ipertensione arteriosa

T2 - benefici, costi, sfide.

AU - Zanchetti, A.

PY - 1996/10

Y1 - 1996/10

N2 - For more than 30 years the benefits of antihypertensive therapy have been assessed by randomized trials measuring cardiovascular events. Even greater benefits are found if prevention of congestive heart failure, left ventricular hypertrophy, and progression to more severe hypertension are considered. Quantifying the benefits in order to calculate cost-effectiveness of treatment is not easy, however. Taking absolute risk and absolute benefit as a guide to treatment decision, though an important approach, may result in limiting therapy to elderly and complicated hypertensives only. Furthermore randomized trials, whose duration is necessarily short, are likely to underestimate treatment benefits. An alternative is the actuarial approach, by which treatment benefits are calculated from the actuarial data showing the reduction in life expectancy associated with any given blood pressure increase. The cost of antihypertensive therapy per year of life gained, as calculated by the actuarial approach, is much lower than the cost calculated on the basis of the outcomes of randomized trials. In an uncertain area such as that of cost-effectiveness evaluation, it is important that both approaches be brought to the consideration of physicians, patients, politicians, and officers of national health systems.

AB - For more than 30 years the benefits of antihypertensive therapy have been assessed by randomized trials measuring cardiovascular events. Even greater benefits are found if prevention of congestive heart failure, left ventricular hypertrophy, and progression to more severe hypertension are considered. Quantifying the benefits in order to calculate cost-effectiveness of treatment is not easy, however. Taking absolute risk and absolute benefit as a guide to treatment decision, though an important approach, may result in limiting therapy to elderly and complicated hypertensives only. Furthermore randomized trials, whose duration is necessarily short, are likely to underestimate treatment benefits. An alternative is the actuarial approach, by which treatment benefits are calculated from the actuarial data showing the reduction in life expectancy associated with any given blood pressure increase. The cost of antihypertensive therapy per year of life gained, as calculated by the actuarial approach, is much lower than the cost calculated on the basis of the outcomes of randomized trials. In an uncertain area such as that of cost-effectiveness evaluation, it is important that both approaches be brought to the consideration of physicians, patients, politicians, and officers of national health systems.

UR - http://www.scopus.com/inward/record.url?scp=0030254793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030254793&partnerID=8YFLogxK

M3 - Articolo

C2 - 9004827

AN - SCOPUS:0030254793

VL - 11 Suppl 2

JO - Annali Italiani di Medicina Interna

JF - Annali Italiani di Medicina Interna

SN - 0393-9340

ER -